Literature DB >> 18359291

17beta-Hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein.

Yuka Horiguchi1, Makoto Araki, Kiyoto Motojima.   

Abstract

17beta-Hydroxysteroid dehydrogenase (17betaHSD) type 13 is identified as a new lipid droplet-associated protein. 17betaHSD type 13 has an N-terminal sequence similar to that of 17betaHSD type 11, and both sequences function as an endoplasmic reticulum and lipid droplet-targeting signal. Localization of native 17betaHSD type 13 on the lipid droplets was confirmed by subcellular fractionation and Western blotting. In contrast to 17betaHSD type 11, however, expression of 17betaHSD type 13 is largely restricted to the liver and is not enhanced by peroxisome proliferator-activated receptor alpha and its ligand. Instead the expression level of 17betaHSD type 13 in the receptor-null mice was increased several-fold. 17betaHSD type 13 may have a distinct physiological role as a lipid droplet-associated protein in the liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359291     DOI: 10.1016/j.bbrc.2008.03.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Authors:  Panu K Luukkonen; Taru Tukiainen; Anne Juuti; Henna Sammalkorpi; P A Nidhina Haridas; Onni Niemelä; Johanna Arola; Marju Orho-Melander; Antti Hakkarainen; Petri T Kovanen; Om Dwivedi; Leif Groop; Leanne Hodson; Amalia Gastaldelli; Tuulia Hyötyläinen; Matej Orešič; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2020-03-12

2.  Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.

Authors:  Carlos J Pirola; Martin Garaycoechea; Diego Flichman; Marco Arrese; Julio San Martino; Carla Gazzi; Gustavo O Castaño; Silvia Sookoian
Journal:  J Lipid Res       Date:  2018-10-15       Impact factor: 5.922

3.  HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment.

Authors:  Michela E Burlone; Mattia Bellan; Matteo N Barbaglia; Ginevra Mocchetti; Venkata R Mallela; Rosalba Minisini; Cristina Rigamonti; Mario Pirisi
Journal:  Clin J Gastroenterol       Date:  2022-01-31

4.  SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species.

Authors:  Pascal Demange; Etienne Joly; Julien Marcoux; Yves Génisson; Remi Chauvin; Patrick R A Zanon; Dymytrii Listunov; Pauline Rullière; Cécile Barthes; Céline Noirot; Jean-Baptiste Izquierdo; Alexandrine Rozié; Karen Pradines; Romain Hee; Maria Vieira de Brito; Marlène Marcellin; Remy-Felix Serre; Olivier Bouchez; Odile Burlet-Schiltz; Maria Conceição Ferreira Oliveira; Stéphanie Ballereau; Vania Bernardes-Génisson; Valérie Maraval; Patrick Calsou; Stephan M Hacker; Sébastien Britton
Journal:  Elife       Date:  2022-05-10       Impact factor: 8.713

5.  Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity.

Authors:  Zhao Zhang; Yu Xun; Shunxing Rong; Lijuan Yan; Jeffrey A SoRelle; Xiaohong Li; Miao Tang; Katie Keller; Sara Ludwig; Eva Marie Y Moresco; Bruce Beutler
Journal:  Nat Commun       Date:  2022-07-16       Impact factor: 17.694

6.  Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity.

Authors:  Yanling Ma; Suman Karki; Philip M Brown; Dennis D Lin; Maren C Podszun; Wenchang Zhou; Olga V Belyaeva; Natalia Y Kedishvili; Yaron Rotman
Journal:  J Lipid Res       Date:  2020-09-24       Impact factor: 5.922

7.  A closer look at the mysterious HSD17B13.

Authors:  X Charlie Dong
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

Review 8.  Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.

Authors:  Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

9.  17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.

Authors:  Yanling Ma; Philip M Brown; Dennis D Lin; Jing Ma; Dechun Feng; Olga V Belyaeva; Maren C Podszun; Jason Roszik; Joselyn N Allen; Regina Umarova; David E Kleiner; Natalia Y Kedishvili; Oksana Gavrilova; Bin Gao; Yaron Rotman
Journal:  Hepatology       Date:  2021-03-16       Impact factor: 17.298

Review 10.  Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.

Authors:  Xuelin Zhang; Yang Wang; Pingsheng Liu
Journal:  Protein Cell       Date:  2016-10-18       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.